Brightstar Resources Limited (BTR) Receives a Buy from Petra Capital
In a report released yesterday, Andrew Richards CFA from Petra Capital maintained a Buy rating on Brightstar Resources Limited (BTR – Research Report), with a price target of A$1.20. The company's shares opened today at A$0.58.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Richards CFA is a 4-star analyst with an average return of 18.3% and a 71.43% success rate. Richards CFA covers the Basic Materials sector, focusing on stocks such as Medallion Metals Ltd, Aurum Resources Limited, and Silver Mines Limited.
Currently, the analyst consensus on Brightstar Resources Limited is a Strong Buy with an average price target of A$1.34, representing a 131.03% upside. In a report released on May 23, Taylor Collison also maintained a Buy rating on the stock with a A$1.38 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
DBS Sticks to Their Buy Rating for Q Technology (Group) Co (1478)
DBS analyst Jim Hin Kwong Au maintained a Buy rating on Q Technology (Group) Co (1478 – Research Report) today. The company's shares opened today at HK$6.59. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hin Kwong Au covers the Technology sector, focusing on stocks such as BYD Electronic (International) Co, Apple, and Sunny Optical Technology (Group) Co. According to TipRanks, Hin Kwong Au has an average return of 8.7% and a 52.59% success rate on recommended stocks. Currently, the analyst consensus on Q Technology (Group) Co is a Moderate Buy with an average price target of HK$9.25. The company has a one-year high of HK$9.26 and a one-year low of HK$3.37. Currently, Q Technology (Group) Co has an average volume of 6.6M.
Business Insider
2 hours ago
- Business Insider
Evercore ISI Sticks to Their Hold Rating for Factset Research (FDS)
Evercore ISI analyst David Motemaden maintained a Hold rating on Factset Research (FDS – Research Report) yesterday and set a price target of $470.00. The company's shares closed yesterday at $433.79. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Motemaden is a 5-star analyst with an average return of 12.2% and a 76.92% success rate. Motemaden covers the Financial sector, focusing on stocks such as Chubb, Arthur J Gallagher & Co, and Factset Research. Factset Research has an analyst consensus of Moderate Sell, with a price target consensus of $441.67, which is a 1.82% upside from current levels. In a report released on June 2, RBC Capital also maintained a Hold rating on the stock with a $503.00 price target. FDS market cap is currently $17.33B and has a P/E ratio of 32.44. Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FDS in relation to earlier this year. Most recently, in March 2025, Katherine M Stepp, the CTO (CTO) of FDS sold 1,725.00 shares for a total of $733,241.68.
Business Insider
2 hours ago
- Business Insider
Leerink Partners Keeps Their Buy Rating on uniQure (QURE)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on uniQure (QURE – Research Report) on June 3 and set a price target of $48.00. The company's shares closed yesterday at $14.96. Confident Investing Starts Here: Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Schwartz has an average return of 10.5% and a 42.05% success rate on recommended stocks. Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $38.40, implying a 156.68% upside from current levels. In a report released on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target. Based on uniQure's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.57 million and a GAAP net loss of $43.64 million. In comparison, last year the company earned a revenue of $8.49 million and had a GAAP net loss of $65.62 million Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year. Most recently, in March 2025, Jeannette Potts, the CLO of QURE sold 7,076.00 shares for a total of $72,812.04.
